1 Nov, 2021 Alzheon to Present New Data from Ongoing Phase 2 Biomarker Trial of ALZ-801 Oral Tablet at Clinical Trials in Alzheimer’s Disease (CTAD) Conference alzheon2021-10-29T17:14:00-04:00November 1st, 2021|Tags: Press Release| Read More
13 Sep, 2021 Alzheon to Present at H.C. Wainwright Annual Global Investment Conference on September 13, 2021 alzheon2021-09-10T16:52:57-04:00September 13th, 2021|Tags: Press Release| Read More
13 Sep, 2021 Alzheon Appoints Adem Albayrak as Head of Operations and Earvin Liang, PhD, as Vice President of Clinical Development alzheon2021-09-10T16:52:05-04:00September 13th, 2021|Tags: Press Release| Read More
23 Jun, 2021 Alzheon Completes Patient Enrollment in Phase 2 Biomarker Trial of ALZ-801 Oral Tablet in APOE4 Carriers with Alzheimer’s Disease alzheon2021-06-22T16:42:46-04:00June 23rd, 2021|Tags: Press Release| Read More
23 Jun, 2021 Peer-Reviewed Scientific Publication Demonstrates Central Role of Neurotoxic Soluble Amyloid Oligomers in Driving Alzheimer’s Pathogenesis alzheon2021-06-22T16:43:14-04:00June 23rd, 2021|Tags: Press Release| Read More
4 Jun, 2021 Alzheon Announces First Patient Dosed in APOLLOE4 Phase 3 Trial of Oral ALZ 801 in Patients with Early Alzheimer’s Disease alzheon2021-06-22T14:16:53-04:00June 4th, 2021|Tags: Press Release| Read More
4 May, 2021 Alzheon Partners with Czech Institute of Organic Chemistry and Biochemistry to Develop First Alzheimer’s Diagnostic Assay for Measuring Neurotoxic Beta Amyloid Oligomers in Human Brain alzheon2021-04-29T18:49:40-04:00May 4th, 2021|Tags: Press Release| Read More
9 Mar, 2021 Alzheon to Present at H.C. Wainwright Global Life Sciences Conference alzheon2021-03-11T14:43:11-05:00March 9th, 2021|Tags: Press Release| Read More
9 Dec, 2020 Alzheon Announces New Research Showing Accelerated Hippocampus Atrophy in APOE4/4 Patients with Early Alzheimer’s Disease alzheon2021-03-11T14:45:51-05:00December 9th, 2020|Tags: Press Release| Read More